Aclaris Therapeutics

Aclaris Therapeutics Advances ATI-1777 into Phase 2b Trial, Plans Workforce Reduction to Preserve Capital

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is making strategic moves, announcing several updates this week including promising trial results, a shift in drug development focus, and a significant …

Aclaris Therapeutics Advances ATI-1777 into Phase 2b Trial, Plans Workforce Reduction to Preserve Capital Read More

US Digestive Health

US Digestive Health Expands Gastroenterology Services in Pennsylvania with Southwest Gastroenterology Associates Partnership

EXTON, PA — US Digestive Health (USDH), one of the nation’s largest gastroenterology practices, is expanding its network and services in Pennsylvania through a strategic partnership with Southwest Gastroenterology Associates …

US Digestive Health Expands Gastroenterology Services in Pennsylvania with Southwest Gastroenterology Associates Partnership Read More
Ocugen

Ocugen’s OCU400 Earns FDA’s RMAT Designation, Enhancing Prospects for Retinitis Pigmentosa Treatment

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a Pennsylvania-based biopharmaceutical company, has scored a significant regulatory milestone this week with the U.S. Food and Drug Administration (FDA) granting Regenerative Medicine …

Ocugen’s OCU400 Earns FDA’s RMAT Designation, Enhancing Prospects for Retinitis Pigmentosa Treatment Read More